Wang YH, Wang W, Jin KZ, Fang C, Lin Y, Xue L, Feng ST, Zhou ZW, Shao CH, Chen MH, et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
Article
PubMed
Google Scholar
Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.
Article
PubMed
Google Scholar
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.
Article
CAS
PubMed
Google Scholar
Masui T, Sato A, Nakano K, Uchida Y, Yogo A, Anazawa T, Nagai K, Kawaguchi Y, Takaori K, Uemoto S. Comparison of recurrence between pancreatic and duodenal neuroendocrine neoplasms after curative resection: a single-institution analysis. Ann Surg Oncol. 2018;25(2):528–34.
Article
PubMed
Google Scholar
Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74–87.
Article
CAS
PubMed
Google Scholar
Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231–42.
Article
PubMed
Google Scholar
Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16.
Article
PubMed
PubMed Central
Google Scholar
Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43(4):526–31.
Article
PubMed
PubMed Central
Google Scholar
Pavel M, de Herder WW. ENETS consensus guidelines for the standard of Care in Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):193–5.
Article
CAS
PubMed
Google Scholar
Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GS, Kim HK, Ko BM, Lee MS. Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors. J Dig Dis. 2015;16(10):595–600.
Article
PubMed
Google Scholar
Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z, Deng Q, Xiong X, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.
Article
PubMed
Google Scholar
Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, Fung JJ, Pawlik TM. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery. 2017;162(3):525–36.
Article
PubMed
Google Scholar
Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200.
Article
CAS
PubMed
Google Scholar
Grillo F, Albertelli M, Brisigotti MP, Borra T, Boschetti M, Fiocca R, Ferone D, Mastracci L. Grade increases in Gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 2016;103(5):452–9.
Article
CAS
PubMed
Google Scholar
Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and systemic approaches for the treatment of patients with metastatic neuroendocrine tumors. J Gastrointest Surg. 2015;19(12):2273–82.
Article
PubMed
Google Scholar
Russolillo N, Vigano L, Razzore P, Langella S, Motta M, Bertuzzo F, Papotti M, Ferrero A. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. Eur J Surg Oncol. 2015;41(6):751–7.
Article
CAS
PubMed
Google Scholar
Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.
Article
CAS
PubMed
Google Scholar
Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2017;161(1):272–9.
Article
PubMed
Google Scholar
Lin CW, Lai CH, Hsu CC, Hsu CT, Hsieh PM, Hung KC, Chen YS. Primary hepatic carcinoid tumor: a case report and review of the literature. Cases J. 2009;2(1):90.
Article
PubMed
PubMed Central
Google Scholar
Chen X, Ren H, Chi Y, He S, Huang Z, Hu X, Zhao H. Resection of postoperative liver metastasis from pancreatic neuroendocrine tumors: report of one case. Transl Gastroenterol Hepatol. 2016;1:47.
Article
PubMed
PubMed Central
Google Scholar
Okuyama H, Ikeda M, Takahashi H, Ohno I, Hashimoto Y, Mitsunaga S, Sakamoto Y, Kondo S, Morizane C, Ueno H, et al. Transarterial (chemo)embolization for liver metastases in patients with neuroendocrine tumors. Oncology. 2017;92(6):353–9.
Article
PubMed
Google Scholar
Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K, Ohshima K, Urakami K, Yamaguchi K. Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res. 2017;38(1):19–27.
Article
CAS
PubMed
Google Scholar
Lv Y, Pu N, Mao W, Chen W, Wang H, Han X, Ji Y, Zhang L, Jin D, Lou W, et al. Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocr Connect. 2018;7(11):1178–85.
Article
PubMed Central
Google Scholar
Lv Y, Han X, Zhang C, Fang Y, Pu N, Ji Y, Wang D, Xuefeng X, Lou W. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr Connect. 2018;7(1):169–78.
Article
CAS
PubMed
Google Scholar
Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995–5005.
Article
PubMed
PubMed Central
Google Scholar
Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115(4):741–51.
Article
PubMed
Google Scholar
Chen JX, Wileyto EP, Soulen MC. Randomized embolization trial for NeuroEndocrine tumor metastases to the liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19(1):390.
Article
PubMed
PubMed Central
Google Scholar
Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother Pharmacol. 2004;53(4):337–40.
Article
CAS
PubMed
Google Scholar